The Radiation Emergency Assistance Center/Training Site (REAC/TS) professionals maintain a registry of clinical information and provide expertise to practitioners worldwide on the use of calcium-diethylenetriaminepentaacetic acid (DTPA) and zinc-diethylenetriaminepentaacetic acid (DTPA) and Radiogardase Prussian Blue (Radiogardase™).
Radiogardase Prussian Blue (Radiogardase™) binds to radiocesium and thallium and enhances their excretion from the body.
Package inserts are available for radiation treatment pharmaceuticals calcium-DTPA, zinc-DTPA and Radiogardase (Prussian Blue).
- Calcium-DTPA package insert (PDF)
- Zinc-DTPA package insert (PDF)
- Radiogardase (Prussian Blue) package insert (PDF)
How to obtain DTPA and Prussian Blue (US/International)
Individual patients by prescription only
McGuff Pharmacy (Monday-Friday, 7 a.m. - 5:30 p.m. PT)
2921 W Macarthur Blvd #142
Santa Ana, CA 92704
Prussian Blue for stockpile
925 South Mason Rd., PMB #242
Katy, Texas 77450
Phone: (281) 395-7040
Fax: (281) 395-2320
Ca and Zn DTPA
- Pentetate Calcium Trisodium Injection
- Pentetate Zinc Trisodium Injection
Golden State Medical Supply (8:30 am - 5:30 p.m. PT)
5187 Camino Ruiz
Camarillo, California 93012
Phone: (805) 477-9866
Prussian Blue/Ca and Zn DTPA
Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
Kurfürstendamm 178 – 179
10707 Berlin | Deutschland
Phone: +49 30 816 96 – 0
Fax: +49 30 817 40 49
REAC/TS has no financial or other interest with the above companies. This is for informational purposes only and is subject to change. We encourage anyone needing these medications to contact the above companies prior to an event.
Nplate® (Romiplostim) approved for use in Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
The National Institute of Allergy and Infectious Diseases (NIAID)/National Institute of Health’s (NIH) Radiation and Nuclear Countermeasures Program (RNCP) announced on January 28, 2021, that the FDA approved application by Amgen for Nplate® (Romiplostim) to add the following indication to the package insert:
“Patients with Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS): Nplate is indicated to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation.”
The RNCP, along with the Division of Allergy, Immunology, and Transplantation (DAIT) Office of Regulatory Affairs and Clinical Research Operations Program, is tremendously proud to have been a part of the team involved in this regulatory approval. In the case of a radiological or nuclear public health emergency, many thousands of people could experience severe injuries from radiation exposure, resulting in immunosuppression and infection, hemorrhage, major morbidities, and even death.
- NIAID-sponsored studies demonstrated that administration of Nplate®, originally licensed in 2008 for treatment of immune thrombocytopenia, increased platelet counts and improved survival in preclinical models of lethal radiation exposure.
- With the January 28, 2021 approval of Nplate® for hematopoietic acute radiation syndrome (H-ARS), the FDA has now granted approvals for four products to treat H-ARS, three of which relied on NIAID-supported preclinical data.
- The FDA Animal Rule approval of Nplate® is the result of a collaboration between NIAID, the Biomedical Advanced Research and Development Authority (BARDA), and Amgen, with NIAID sponsoring the pivotal studies that were the basis for the approval.
- Nplate® represents a new class of molecules to target radiation-induced hemorrhage by increasing platelet counts. The survival benefit of Nplate® appears to be additive to that of existing approved products, providing an extra dimension to the treatment of H-ARS.
What is DTPA?
DTPA injectable chelating agents used to enhance the excretion of plutonium and other transuranics from the body. DTPA comes in two forms—calcium (Ca-DTPA) and zinc (Zn-DTPA)—both of which bind to radioactive plutonium, americium, and curium. Watch the video to learn more about DTPA and its use in radiation exposure treatment.
What is Prussian Blue?
Prussian Blue is an ingestable capsule that helps remove radioactive cesium and thallium from the body. One of Prussian Blue's advantages is that it reduces amount of time the body is exposed to radiation. Watch the video to learn more about Prussian Blue (Radiogardase) and its use in the treatment of acute radiation exposure.